Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 83 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: L-dopa Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Autonomic Nervous System and Chronic Fatigue Syndrome

NCT00580619
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Orthostatic Intolerance, Postural Tachycardia Syndrome
Interventions
Autonomic Function Testing, Saline infusions, L-NMMA trimethaphan, methyldopa
Other · Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 2 Interventional

Riluzole to Treat Parkinson's Disease

NCT00013624
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IV Levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 17, 2026, 3:21 AM EDT
Not listed Phase 1Phase 2 Interventional

A Study of IBRF Disorders of Consciousness Advanced Care/MultiModal Care Protocol in Severe Disorders of Consciousness

NCT02696512
View directory record Official record
Conditions
Brain Injury
Interventions
Polypharmacy using FDA-approved products, Median Nerve Stimulation (MNS), Nutraceutical Supplementation, Standard of Care
Drug · Device · Dietary Supplement + 1 more
Lead sponsor
International Brain Research Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Not applicable Interventional

Deep Brain Stimulation to Treat Symptoms of Parkinson's Disease

NCT00552474
View directory record Official record
Conditions
Parkinson Disease, Movement Disorders
Interventions
Libra Deep Brain Stimulation System
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 80 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
15
States / cities
Loma Linda, California • Gainesville, Florida • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Levodopa Pharmacokinetics Following Single Dose Administration of CVT 301 (Levodopa Inhalation Powder) in Smoking and Non-Smoking Adults

NCT02633839
View directory record Official record
Conditions
Smoking
Interventions
CVT-301, Carbidopa
Drug
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Daytona Beach, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Results available

Study on Tolerability of Levodopa/Carbidopa in Children With Angelman Syndrome

NCT00829439
View directory record Official record
Conditions
Angelman Syndrome
Interventions
Levodopa/Carbidopa (4:1)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
4 Years to 12 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Results available

Phase II Safety and Efficacy Study of 18FDOPA PET-CT in Children With Hyperinsulinemic Hypoglycemia

NCT01468454
View directory record Official record
Conditions
Congenital Hyperinsulinism (CHI), Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Interventions
18 F-DOPA
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of a Pre-Workout Dietary Supplement

NCT02952014
View directory record Official record
Conditions
Dietary Modification
Interventions
C4 Extreme, C4 Extreme (without Advantra Z, Placebo
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
18 Years to 40 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 17, 2026, 3:21 AM EDT
Available No phase listed Expanded access

18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Subjects With Hyperinsulinemic Hypoglycemia

NCT01916148
View directory record Official record
Conditions
Congenital Hyperinsulinism (CHI), Beckwith-Wiedemann Syndrome, Insulinoma
Interventions
18F-DOPA
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 17, 2026, 3:21 AM EDT
Not listed No phase listed Observational

Substance Abuse Pre-Treatment Screening Study

NCT00439049
View directory record Official record
Conditions
Cocaine Abuse, Cocaine Dependence, Opiate Dependence, Alcohol Dependence, Substance Abuse
Interventions
modafinil, d-amphetamine, L-Dopa, Naltrexone
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 60 Years
Enrollment
7,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 20, 2023 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Modulating Glucose Tolerance With Dietary Tyrosine

NCT03872557
View directory record Official record
Conditions
Glucose Tolerance
Interventions
Tyrosine (TYR) Supplementation
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Oct 17, 2026, 3:21 AM EDT
Completed No phase listed Observational

Observational, Long-term Extension Study for Participants of Prior VY-AADC01 Studies

NCT03733496
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years and older
Enrollment
14 participants
Timeline
2018 – 2023
U.S. locations
3
States / cities
San Francisco, California • Atlanta, Georgia • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 17, 2026, 3:21 AM EDT
Not yet recruiting Phase 4 Interventional

Gastrointestinal Dopamine Decarboxylase and Levodopa Pharmacokinetics

NCT07793461
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa (L-dopa)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Study of SYN115 in Parkinson's Patients Using Levodopa to Treat End of Dose Wearing Off

NCT01283594
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Tozadenant (SYN115) 60 mg BID, Placebo, Levodopa (L-dopa), Tozadenant (SYN115) 120 mg BID, Tozadenant (SYN115) 180 mg BID, Tozadenant (SYN115) 240 mg BID
Drug
Lead sponsor
Biotie Therapies Inc.
Industry
Eligibility
30 Years to 80 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • La Jolla, California • Loma Linda, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 1 Interventional

Treatment of Supine Hypertension in Autonomic Failure

NCT00223717
View directory record Official record
Conditions
Hypertension
Interventions
Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress
Drug · Dietary Supplement · Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2017 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 1 Interventional

VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1)

NCT03562494
View directory record Official record
Conditions
Parkinson's Disease
Interventions
VY-AADC02, Sham (Placebo) Surgery
Biological · Other
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
40 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
11
States / cities
Irvine, California • Sacramento, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Early Phase 1 Interventional

Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma

NCT01165632
View directory record Official record
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymal Giant Cell Astrocytoma, Adult Subependymoma
Interventions
biopsy, computed tomography, therapeutic conventional surgery, radiation therapy treatment planning/simulation, radiation therapy, magnetic resonance imaging, positron emission tomography, fluorine F 18 fluorodopa
Procedure · Radiation · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach

NCT03266965
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Carbidopa, L-Histidine
Drug · Dietary Supplement
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 17, 2026, 3:21 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Proof of Mechanism Study for the Treatment of Social Anhedonia in ASD

NCT03243552
View directory record Official record
Conditions
ASD
Interventions
L-DOPA versus Placebo, Social Skills Training
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 30 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 3 Interventional

Timing of Levodopa Treatment in Parkinson's Disease

NCT00004733
View directory record Official record
Conditions
Parkinson's Disease
Interventions
levodopa
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Results available

New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome

NCT00001849
View directory record Official record
Conditions
Cushing Syndrome, Endocrine Disease
Interventions
Pentetreotide, 18F-DOPA, CT scan, MRI, 18-FDG
Drug · Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
18 Years to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 2 Interventional Results available

Trial of L-DOPA as a Treatment to Improve Vision in Albinism

NCT01176435
View directory record Official record
Conditions
Albinism
Interventions
Levodopa, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
3 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 17, 2026, 3:21 AM EDT
Active, not recruiting Phase 2 Interventional

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

NCT05781321
View directory record Official record
Conditions
Glioblastoma
Interventions
Accelerated Hypofractionated Radiation Therapy, Computed Tomography, Fluorodopa F 18, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide, Biospecimen Collection
Radiation · Procedure · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 17, 2026, 3:21 AM EDT
Completed Phase 4 Interventional Results available

DTA (Dopaminergic Therapy for Anhedonia) Study

NCT04723147
View directory record Official record
Conditions
Depression, Anhedonia
Interventions
Carbidopa Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
25 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2024 · Synced Oct 17, 2026, 3:21 AM EDT